Drugs to block cytokine signaling for the prevention and treatment of inflammation induced preterm birth

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Ng, Pearl Y ^a   Ireland, Demelza J ^a   Keelan, Jeffrey A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Chorioamnionitis; Cytokine suppressive anti inflammatory drugs (CSAIDs); Intrauterine infection; Intrauterine inflammation; NF B inhibitors; Preterm birth

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL) IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL] CYCLOHEXANOL; 5Z 7 OXOZEAENOL; 6 (4 FLUOROPHENYL) 2, 3 DIHYDRO 5 (4 PYRIDYL) IMIDAZO [2, 1 B] THIAZOLE; ANTIINFLAMMATORY AGENT; CYTOKINE; CYTOKINE SUPPRESSIVE ANTIINFLAMMATORY DRUG; ERITORAN; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; NONSTEROID ANTIINFLAMMATORY AGENT; PARTHENOLIDE; PROSTAGLANDIN; RESATORVID; SALAZOSULFAPYRIDINE; SOLITHROMYCIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CHEMOTHERAPY; CHORIOAMNIONITIS; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATION; INTRAUTERINE INFECTION; METABOLIC INHIBITION; NONHUMAN; PATHOGENESIS; PREMATURE LABOR; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX DISEASE;

EID: 84926664321     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00166     Document Type: Article

References (92)

1. Chang HH, Larson J, Blencowe H, Spong CY, Howson CP, Cairns-Smith S, et al. Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index. Lancet. 2013;381(9862):223-34. Epub 2012/11/20.
2. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. The Lancet. 2008;371(9606):75-84.
3. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162-72. Epub 2012/06/12.
4. Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, et al. The preterm parturition syndrome. BJOG: an international journal of obstetrics and gynaecology. 2006;113 Suppl 3:17-42.
5. Dando SJ, Nitsos I, Polglase GR, Newnham JP, Jobe AH, Knox CL. Ureaplasma parvum undergoes selection in utero resulting in genetically diverse isolates colonizing the chorioamnion of fetal sheep. Biology of reproduction. 2014;90(2):27. Epub 2013/12/18.
6. Goldenberg RL, Culhane JF, Iams JD, Romero R. Preterm birth 1-Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75-84.
7. DiGiulio DB, Romero R, Kusanovic JP, Gomez R, Kim CJ, Seok KS, et al. Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. American journal of reproductive immunology (New York, NY: 1989). 2010;64(1):38-57. Epub 2010/03/25.
8. Rinaldi SF, Hutchinson JL, Rossi AG, Norman JE. Anti-inflammatory mediators as physiological and pharmacological regulators of parturition. Expert review of clinical immunology. 2011;7(5):675-96. Epub 2011/09/08.
9. Galinsky R, Polglase GR, Hooper SB, Black MJ, Moss TJ. The consequences of chorioamnionitis: preterm birth and effects on development. Journal of pregnancy. 2013;2013:412831. Epub 2013/03/28.
10. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. American journal of obstetrics and gynecology. 1998;179(1):194-202. Epub 1998/08/15.
11. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2011;38(1):18-31. Epub 2011/04/08.
12. Keelan JA. Pharmacological inhibition of inflammatory pathways for the prevention of preterm birth. Journal of reproductive immunology. 2011;88(2):176-84. Epub 2011/01/18.
13. Romero R, Gómez R, Chaiworapongsa T, Conoscenti G, Cheol Kim J, Mee Kim Y. The role of infection in preterm labour and delivery. Paediatric and Perinatal Epidemiology. 2001;15:41-56.
14. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel LA, Nien JK. Inflammation in preterm and term labour and delivery. Seminars in fetal & neonatal medicine. 2006;11(5):317-26. Epub 2006/07/15.
15. Lockwood CJ. Predicting premature delivery-no easy task. The New England journal of medicine. 2002;346(4):282-4. Epub 2002/01/25.
16. Czikk MJ, McCarthy FP, Murphy KE. Chorioamnionitis: from pathogenesis to treatment. Clinical Microbiology and Infection. 2011;17(9):1304-11.
17. Pappas A, Kendrick DE, Shankaran S, Stoll BJ, Bell EF, Laptook AR, et al. Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates. JAMA pediatrics. 2014;168(2):137-47. Epub 2014/01/01.
18. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel L, Hassan S. The role of inflammation and infection in preterm birth. Semin Reprod Med. 2007;25(1):21-39. Epub 2007/01/06.
19. Combs CA, Gravett M, Garite TJ, Hickok DE, Lapidus J, Porreco R, et al. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. American journal of obstetrics and gynecology. 2014;210(2):125 e1-e15. Epub 2013/11/28.
20. Keelan JA, Blumenstein M, Helliwell RJ, Sato TA, Marvin KW, Mitchell MD. Cytokines, prostaglandins and parturition-a review. Placenta. 2003;24 Suppl A:S33-46. Epub 2003/07/05.
21. Kemp MW, Saito M, Newnham JP, Nitsos I, Okamura K, Kallapur SG. Preterm birth, infection, and inflammation advances from the study of animal models. Reproductive sciences. 2010;17(7):619-28. Epub 2010/06/29.
22. Ratajczak CK, Muglia LJ. Insights Into Parturition Biology From Genetically Altered Mice. Pediatr Res. 2008;64(6):581-9.
23. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature immunology. 2010;11(5):373-84. Epub 2010/04/21.
24. Takeda K, Akira S. Toll-like receptors in innate immunity. International immunology. 2005;17(1):1-14. Epub 2004/12/09.
25. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harbor perspectives in biology. 2009;1(4):a000034.
26. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes & development. 2004;18(18):2195-224.
27. Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as anti-inflammatory drug targets. Journal of dental research. 2007;86(9):800-11. Epub 2007/08/28.
28. Lappas M, Permezel M, Rice GE. Mitogen-activated protein kinase proteins regulate LPS-stimulated release of pro-inflammatory cytokines and prostaglandins from human gestational tissues. Placenta. 2007;28(8-9):936-45. Epub 2007/04/17.
29. Flenady V, Hawley G, Stock OM, Kenyon S, Badawi N. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database Syst Rev. 2013;12:CD000246. Epub 2013/12/07.
30. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. The Cochrane database of systematic reviews. 2010(8):CD001058. Epub 2010/08/06.
31. King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev. 2005(2):CD001992. Epub 2005/04/23.
32. Haas DM, Imperiale TF, Kirkpatrick PR, Klein RW, Zollinger TW, Golichowski AM. Tocolytic therapy: a meta-analysis and decision analysis. Obstetrics and gynecology. 2009;113(3):585-94. Epub 2009/03/21.
33. Loudon JA, Groom KM, Bennett PR. Prostaglandin inhibitors in preterm labour. Best practice & research Clinical obstetrics & gynaecology. 2003;17(5):731-44. Epub 2003/09/16.
34. Zafarullah M, Li W, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. CMLS, Cell Mol Life Sci. 2003;60(1):6-20.
35. Lappas M, Permezel M, Rice GE. N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-kappaB deoxyribonucleic acid-binding activity in human fetal membranes in vitro. J Clin Endocrinol Metab. 2003;88(4):1723-9. Epub 2003/04/08.
36. Stinson LF, Ireland DJ, Kemp MW, Payne MS, Stock SJ, Newnham JP, et al. Effects of cytokine-suppressive anti-inflammatory drugs on inflammatory activation in ex vivo human and ovine fetal membranes. Reproduction. 2014;147(3):313-20. Epub 2014/02/05.
37. Shahin AY, Hassanin IM, Ismail AM, Kruessel JS, Hirchenhain J. Effect of oral N-acetyl cysteine on recurrent preterm labor following treatment for bacterial vaginosis. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2009;104(1):44-8. Epub 2008/10/15.
38. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000;119(5):1209-18. Epub 2000/10/31.
39. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reproductive toxicology (Elmsford, NY). 2008;25(2):271-5. Epub 2008/02/05.
40. Keelan JA, Khan S, Yosaatmadja F, Mitchell MD. Prevention of inflammatory activation of human gestational membranes in an ex vivo model using a pharmacological NF-kappaB inhibitor. Journal of immunology (Baltimore, Md: 1950). 2009;183(8):5270-8. Epub 2009/09/29.
41. Nath CA, Ananth CV, Smulian JC, Peltier MR. Can sulfasalazine prevent infection-mediated pre-term birth in a murine model? American journal of reproductive immunology (New York, NY: 1989). 2010;63(2):144-9. Epub 2009/12/31.
42. Adams Waldorf KM, Persing D, Novy MJ, Sadowsky DW, Gravett MG. Pretreatment with toll-like receptor 4 antagonist inhibits lipopolysaccharide-induced preterm uterine contractility, cytokines, and prostaglandins in rhesus monkeys. Reproductive sciences (Thousand Oaks, Calif). 2008;15(2):121-7. Epub 2008/01/12.
43. Li L, Kang J, Lei W. Role of Toll-like receptor 4 in inflammation-induced preterm delivery. Mol Hum Reprod. 2010;16(4):267-72. Epub 2009/12/10.
44. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem. 2004;4(11):1147-71. Epub 2004/07/29.
45. Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol. 2011;79(1):34-41. Epub 2010/10/01.
46. Fidel PL, Jr., Romero R, Cutright J, Wolf N, Gomez R, Araneda H, et al. Treatment with the interleukin-I receptor antagonist and soluble tumor necrosis factor receptor Fc fusion protein does not prevent endotoxin-induced preterm parturition in mice. Journal of the Society for Gynecologic Investigation. 1997;4(1):22-6. Epub 1997/01/01.
47. Holmgren C, Esplin MS, Hamblin S, Molenda M, Simonsen S, Silver R. Evaluation of the use of anti-TNF-alpha in an LPS-induced murine model. Journal of reproductive immunology. 2008;78(2):134-9. Epub 2008/04/25.
48. El Mourabet M, El-Hachem S, Harrison JR, Binion DG. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets. 2010;11(2):234-41. Epub 2009/11/18.
49. Geiler J, Buch M, McDermott MF. Anti-TNF treatment in rheumatoid arthritis. Current pharmaceutical design. 2011;17(29):3141-54. Epub 2011/08/26.
50. Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reproductive toxicology (Elmsford, NY). 2011;32(1):93-7. Epub 2011/05/31.
51. Nielsen OH, Loftus EV, Jr., Jess T. Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC medicine. 2013;11:174. Epub 2013/08/02.
52. di Meglio P, Ianaro A, Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis and rheumatism. 2005;52(3):951-8. Epub 2005/03/08.
53. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. The Journal of pharmacology and experimental therapeutics. 2000;293(1):281-8. Epub 2000/03/29.
54. Ward KW, Proksch JW, Azzarano LM, Salyers KL, McSurdy-Freed JE, Molnar TM, et al. SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization. Pharmaceutical research. 2001;18(9):1336-44. Epub 2001/10/31.
55. Sullivan MHF, Alvi SA, Brown NL, Elder MG, Bennett PR. The effects of a cytokine suppressive anti-inflammatory drug on the output of prostaglandin E2 and interleukin-1β from human fetal membranes. Molecular human reproduction. 2002;8(3):281-5.
56. LaMarca HL, Dash PR, Vishnuthevan K, Harvey E, Sullivan DE, Morris CA, et al. Epidermal growth factor-stimulated extravillous cytotrophoblast motility is mediated by the activation of PI3-K, Akt and both p38 and p42/44 mitogen-activated protein kinases. Human reproduction (Oxford, England). 2008;23(8):1733-41. Epub 2008/05/20.
57. Vaillancourt C, Lanoix D, Le Bellego F, Daoud G, Lafond J. Involvement of MAPK signalling in human villous trophoblast differentiation. Mini reviews in medicinal chemistry. 2009;9(8):962-73.
58. May MJ, Marienfeld RB, Ghosh S. Characterization of the Ikappa B-kinase NEMO binding domain. J Biol Chem. 2002;277(48):45992-6000. Epub 2002/09/24.
59. May MJ, D'Acquisto F, Madge LA, Glöckner J, Pober JS, Ghosh S. Selective Inhibition of NF-κB Activation by a Peptide That Blocks the Interaction of NEMO with the I?B Kinase Complex. Science (New York, NY). 2000;289(5484):1550-4.
60. Shibata W, Maeda S, Hikiba Y, Yanai A, Ohmae T, Sakamoto K, et al. Cutting edge: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol. 2007;179(5):2681-5. Epub 2007/08/22.
61. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. The Journal of pharmacology and experimental therapeutics. 2005;312(1):373-81. Epub 2004/08/19.
62. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001;8(8):759-66. Epub 2001/08/22.
63. De Silva D, Mitchell MD, Keelan JA. Inhibition of choriodecidual cytokine production and inflammatory gene expression by selective I-kappaB kinase (IKK) inhibitors. British journal of pharmacology. 2010;160(7):1808-22. Epub 2010/07/24.
64. Ireland DJ, Kemp, M.W., Miura, Y., Saito, M., Newnham, J.P., Keelan, J.A. Intraamniotic pharmacological blockade of inflammatory signalling pathways in an ovine chorioamnionitis mode. Molecular Human Reproduction. 2015;in press (accepted 27th January 2015).
65. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nature immunology. 2005;6(11):1087-95. Epub 2005/09/28.
66. Wu J, Powell F, Larsen NA, Lai Z, Byth KF, Read J, et al. Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol. ACS chemical biology. 2013;8(3):643-50. Epub 2013/01/01.
67. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, Shiina M, et al. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. The Journal of biological chemistry. 2003;278(20):18485-90. Epub 2003/03/08.
68. Neubert M, Ridder DA, Bargiotas P, Akira S, Schwaninger M. Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia. Cell Death Differ. 2011;18(9):1521-30. Epub 2011/04/09.
69. Acuna UM, Wittwer J, Ayers S, Pearce CJ, Oberlies NH, De Blanco EJ. Effects of (5Z)-7-oxozeaenol on the oxidative pathway of cancer cells. Anticancer Res. 2012;32(7):2665-71. Epub 2012/07/04.
70. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell research. 2002;12(1):9-18.
71. Lamont RF, Sawant SR. Infection in the prediction and antibiotics in the prevention of spontaneous preterm labour and preterm birth. Minerva ginecologica. 2005;57(4):423-33. Epub 2005/09/20.
72. Keelan JA, Kemp MW, Payne MS, Johnson D, Stock SJ, Saito M, et al. Maternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model. Antimicrobial agents and chemotherapy. 2014;58(1):447-54. Epub 2013/11/06.
73. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harbor perspectives in biology. 2009;1(6):a001651. Epub 2010/05/12.
74. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nature reviews Drug discovery. 2003;2(9):717-26. Epub 2003/09/03.
75. Li Z-W, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, et al. The IKKβ subunit of I?B kinase (IKK) is essential for nuclear factor ?B activation and prevention of apoptosis. The Journal of experimental medicine. 1999;189(11):1839-45.
76. Theodora M, Antsaklis A, Blanas K, Antsaklis P, Daskalakis G, Sindos M, et al. Risk for fetal loss and prematurity after 12, 413 second trimester amniocenteses in a single center. J Perinat Med. 2014. Epub 2014/12/09.
77. Goncalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. Mental retardation and developmental disabilities research reviews. 2002;8(1):3-13. Epub 2002/03/29.
78. Menon R, Torloni MR, Voltolini C, Torricelli M, Merialdi M, Betrán AP, et al. Biomarkers of spontaneous preterm birth: an overview of the literature in the last four decades. Reproductive Sciences. 2011;18(11):1046-70.
79. Hassan S, Romero R, Hendler I, Gomez R, Khalek N, Espinoza J, et al. A sonographic short cervix as the only clinical manifestation of intra-amniotic infection. Journal of perinatal medicine. 2006;34(1):13-9. Epub 2006/02/24.
80. Romero R, Miranda J, Chaiworapongsa T, Chaemsaithong P, Gotsch F, Dong Z, et al. Sterile Intra-amniotic Inflammation in Asymptomatic Patients with a Sonographic Short Cervix: Prevalence and Clinical Significance. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2014:1-52. Epub 2014/08/16.
81. Gomez R, Romero R, Nien JK, Chaiworapongsa T, Medina L, Kim YM, et al. A short cervix in women with preterm labor and intact membranes: a risk factor for microbial invasion of the amniotic cavity. Am J Obstet Gynecol. 2005;192(3):678-89. Epub 2005/03/05.
82. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. The Cochrane database of systematic reviews. 2013;1:CD000262. Epub 2013/02/27.
83. Keelan JA, Pugazhenthi K. Trans-placental passage and anti-inflammatory effects of solithromycin in the human placenta. Placenta. 2014.
84. Perregaux DG, Dean D, Cronan M, Connelly P, Gabel CA. Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence. Molecular pharmacology. 1995;48(3):433-42. Epub 1995/09/01.
85. Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation. 2004;109(10):1196-205. Epub 2004/03/17.
86. Kim JH, Studer RK, Vo NV, Sowa GA, Kang JD. p38 MAPK inhibition selectively mitigates inflammatory mediators and VEGF production in AF cells co-cultured with activated macrophage-like THP-1 cells. Osteoarthritis and Cartilage. 2009;17(12):1662-9.
87. Smolinski AT, Pestka JJ. Modulation of lipopolysaccharide-induced proinflammatory cytokine production in vitro and in vivo by the herbal constituents apigenin (chamomile), ginsenoside Rb1 (ginseng) and parthenolide (feverfew). Food and Chemical Toxicology. 2003;41(10):1381-90.
88. Kiuchi H, Takao T, Yamamoto K, Nakayama J, Miyagawa Y, Tsujimura A, et al. Sesquiterpene Lactone Parthenolide Ameliorates Bladder Inflammation and Bladder Overactivity in Cyclophosphamide Induced Rat Cystitis Model by Inhibiting Nuclear Factor-?B Phosphorylation. The Journal of Urology. 2009;181(5):2339-48.
89. Kondo Y, Fukuda K, Adachi T, Nishida T. Inhibition by a selective IkappaB kinase-2 inhibitor of interleukin-1-induced collagen degradation by corneal fibroblasts in three-dimensional culture. Invest Ophthalmol Vis Sci. 2008;49(11):4850-7. Epub 2008/08/05.
90. Song Z, Zhu X, Jin R, Wang C, Yan J, Zheng Q, et al. Roles of the kinase TAK1 in CD40-mediated effects on vascular oxidative stress and neointima formation after vascular injury. PloS one. 2014;9(7):e101671. Epub 2014/07/23.
91. Millea PJ. N-acetylcysteine: multiple clinical applications. American family physician. 2009;80(3):265-9. Epub 2009/07/23.
92. Chang EY, Zhang J, Sullivan S, Newman R, Singh I. N-acetylcysteine attenuates the maternal and fetal proinflammatory response to intrauterine LPS injection in an animal model for preterm birth and brain injury. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2011;24(5):732-40. Epub 2011/01/12.